Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease (Phase 2)
2017-000149-30Phase 2Unknown
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD) comparing Pirfenidone arm with Placebo arm (2 arms). Primary endpoint: Primary composite endpoint (FVC decline or death at 52 weeks). Status: unknown.
02
Drugs
pirfenidone
03
Conditions
Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD)
Beyond the preview
Go deeper on 2017-000149-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000149-30.